PD07-02 DIVIDING PATHOLOGICALLY UPSTAGED T3A RENAL CELL CARCINOMA BASED ON CLINICAL T STAGE AT PRESENTATION IS ASSOCIATED WITH IMPROVED ALIGNMENT OF OUTCOMES: A CALL FOR TNM REVISION

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance I (PD07)1 Apr 2019PD07-02 DIVIDING PATHOLOGICALLY UPSTAGED T3A RENAL CELL CARCINOMA BASED ON CLINICAL T STAGE AT PRESENTATION IS ASSOCIATED WITH IMPROVED ALIGNMENT OF OUTCOMES: A CALL FOR TNM REVISION Zachary Hamilton*, Umberto Capitanio, Deepak Pruthi, Alessandro Larcher, Ahmet Bindayi, Stephen Ryan, Ahmed Eldefrawy, Margaret Meagher, Kendrick Yim, Sunil Patel, Brittney Cotta, Aaron Bradshaw, Fang Wan, Thomas McGregor, Francesco Montorsi, and Ithaar Derweesh Zachary Hamilton*Zachary Hamilton* More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Deepak PruthiDeepak Pruthi More articles by this author , Alessandro LarcherAlessandro Larcher More articles by this author , Ahmet BindayiAhmet Bindayi More articles by this author , Stephen RyanStephen Ryan More articles by this author , Ahmed EldefrawyAhmed Eldefrawy More articles by this author , Margaret MeagherMargaret Meagher More articles by this author , Kendrick YimKendrick Yim More articles by this author , Sunil PatelSunil Patel More articles by this author , Brittney CottaBrittney Cotta More articles by this author , Aaron BradshawAaron Bradshaw More articles by this author , Fang WanFang Wan More articles by this author , Thomas McGregorThomas McGregor More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Ithaar DerweeshIthaar Derweesh More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555235.06238.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Pathological upstaged pT3a for Renal Cell Carcinoma (RCC) may have a wide variance in outcomes. We sought to redefine and reclassify pT3a RCC. We investigated recurrence and survival outcomes in pT3a disease and aimed to better categorize this cohort for improvement on current TMN staging. METHODS: Multicenter retrospective analysis of patients with cT1-3aN0M0 RCC who underwent radical or partial nephrectomy. After comparison of outcomes between pT1, pT2 and pT3a, patients were substratified within the pT3a category based on presenting clinical stage. Survival outcomes in T3a RCC were compared based on initial presenting clinical T stage. Comparison was drawn between pT1, pT2 and the subdivided pT3a group (cT1→pT3a, cT2→pT3a, and cT3a→pT3a). Primary outcome was recurrence free survival (RFS). Secondary outcome was overall survival (OS). Multivariable (MVA) and Kaplan-Meier (KM) analysis were conducted to elucidate risk factors and outcomes. RESULTS: We analyzed 2573 patients (1223 RN/1350 PN, median follow up 50.8 months). On MVA, higher clinical stage was a proportionally increasing predictor for risk of upstaging [compared to cT1a, OR of upstaging for cT1b, cT2a and cT2b was 2.6, 6.5, and 14.1, p<0.001] and recurrence [compared to cT1a upstaged to pT3a, HR for cT1b, cT2a, and cT2b upstaged to pT3a was 1.04 (p=0.912), 2.59 (p=0.008), and 2.7 (p=0.009)]. With regards to RFS, when pT3a was subdivided based on presenting clinical stage, significant differences in RFS emerged which aligned differently. Compared to 5 year RFS of pT1 (94.4%), cT1→pT3a aligned with pT2 (76.6% and 81.2%, p=0.346) while cT2→pT3a aligned with cT3a→pT3a 47.4% and 44.0%, p=0.815). With regards to OS, a similar alignment was noted for 5 year OS after subdivision, where pT1 was 89.9%, while cT1→pT3a correlated with pT2 (79.8% and 83.1%, p=0.640) and cT2→pT3a correlated with cT3a→pT3a 67.0% and 64.2%; p=0.893). CONCLUSIONS: Risk of upstaging to pT3a disease and subsequent recurrence is proportional to clinical stage at presentation. Patients with cT1→pT3a have outcomes more similar to pT2, while patients with cT2→pT3a align more closely to cT3a→pT3a. Future refinements of the TNM staging system for RCC should consider re-grouping cT1→pT3a into the pT2 group. Source of Funding: Stephen Weissman Kidney Cancer Research Fund St Louis, MO; Milan, Italy; Kingston, Canada; Milan, Italy; San Diego, CA; Kingston, Canada; Milan, Italy; San Diego, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e142-e143 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Zachary Hamilton* More articles by this author Umberto Capitanio More articles by this author Deepak Pruthi More articles by this author Alessandro Larcher More articles by this author Ahmet Bindayi More articles by this author Stephen Ryan More articles by this author Ahmed Eldefrawy More articles by this author Margaret Meagher More articles by this author Kendrick Yim More articles by this author Sunil Patel More articles by this author Brittney Cotta More articles by this author Aaron Bradshaw More articles by this author Fang Wan More articles by this author Thomas McGregor More articles by this author Francesco Montorsi More articles by this author Ithaar Derweesh More articles by this author Expand All Advertisement PDF downloadLoading ...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.